医药行业上市公司财务分析-----以云南白药为例.doc

医药行业上市公司财务分析以云南白药为例 以云南白药为例 院系名称 姓　　名 学　　号 专　　业 指导教师 2011年 4月 25 日 摘　要 医药行业是本世纪最具发展潜力的行业之一，据预测中国生物技术类药物每年将以不低于25%的速度增长，因此生物制药上市公司的股票备受投资者的青睐。医药行业之间的竞争不断加剧，该行业面临着巨大的发展潜力，同时也承受着极大的风险。 云南白药集团股份有限公司（以下简称云南白药）作为国内大型的医药集团，在其发展中也面临很多问题。怎样在未来一段时间内继续保持较快的发展势头? “云南白药”目前的极低的“省外市场”和“国际市场”份额与“中华民族品牌”声誉不相匹配,如何才能扩大“省外”和“国外”市场份额?作为中成药医药企业,在受国外主流市场准入限制的情况下“云南白药”怎样才能走出符合自身特色的国际化道路?在新的形势下,如何巩固“云南白药”的核心竞争力?这些都是云南白药所面临的问题。 本文根据公司财务分析的相关理论，结合医药行业的特殊性，分析云南白药的财务状况，对云南白药的前景作出理性的分析和预测。通过本文的分析，希望能给医药行业的决策者、准备在医药行业进行投资的企业家、政府官员以及密切关注医药行业的众多投资者提供信息和参考。 关键词：医药行业 ； 云南白药； 财务分析?MACROBUTTON NoMacro [Click and type abstract text here1.] Abstract Pharmaceutical industry is the most development potential of this century one of the industries, according to forecasts China#039;s biotech drugs will be not less than 25% of the annual rate of growth, the biopharmaceutical company#039;s stock listing was highly favored by investors. Competition between the pharmaceutical industry growing, the industry faces enormous development potential, but also bear great risks. Yunnanbaiyao as a large domestic pharmaceutical group, in its development also faces many problems. In the next period of time how to keep the momentum of rapid development? ;Yunnanbaiyao; The current very low, ;Foreign Market; and ;international market; share and ;Chinese brand; reputation does not match, how to expand the ;province outside ;and; foreign ;market share? as a proprietary pharmaceutical companies, in the mainstream market access restrictions by foreign circumstances,; Yunnanbaiyao ;how to get out of line with its own unique path of internationalization? in the new situation, how to consolidate; Yunnanbaiyao; core competence? These are the problems faced by Yunnanbaiyao. According to the theory of financial analysis, combined with the special nature of the pharmaceutical industry, analysis Yunnanbaiyao#039;s financial situation, the prosp